Please be informed that Onxeo SA will be admitted to trading and official listing on NASDAQ OMX Copenhagen. First day of trading is 1 August 2014.
The merger between Onxeo (previously BioAlliance Pharma SA) and Topotarget has been adopted at the companies’ shareholder meetings and approved by the relevant authorities. Topotarget is the dis-continuing company. Onxeo SA has its primary listing on Euronext Paris.
|Volume:||31,482,333 shares (DKK 7,870,583.25)|
|Face value:||EUR 0.25|
|Voting rights of listed capital:||Full|
|Financial year:||1 January to 31 December|
|Unlisted capital:||EUR 0|
|French Organization number:||410 910 095 RCS|
|Average Daily Turnover:||Will be calculated by the French FSA|
|Market Segment / no||OMX CPH Equities / 14|
|Tick Size /no||XCSE Equities, DKK / 7|
Industry Classification Benchmark (ICB)
For further information, please contact: Asta Jepsen, Surveillance, tel. +45 33 93 33 66